Skip to content

Pharminent

cropped-neurology_aaic_banner_frontpage_2026-07-15-1.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Trump executive order lifts psychedelics biotechs
  • Policy / Pricing

Trump executive order lifts psychedelics biotechs

BioPharma Dive

Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more investable space.

Policy / PricingNeuroscienceRead full story

pharminent April 21, 2026 (Last updated: April 21, 2026)

BioPharma Dive

Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more investable space.

Policy / PricingNeuroscienceRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: RFK Jr. defends HHS tenure, 12% proposed budget cut
Next: Asahi Kasei acquires German company Aicuris

Related Stories

  • Policy / Pricing

US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028

pharminent July 22, 2026
  • Policy / Pricing

UK commits to pharma IP protection in Swiss trade deal

pharminent July 16, 2026
  • Policy / Pricing

Germany approves healthcare costs overhaul despite significant pharma opposition

pharminent July 13, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.